November 17, 2022
Anivive Sponsors National Academy of Sciences Valley Fever Workshop
January 12, 2022
Anivive Licenses Novel Canine Cancer Therapeutic to Expand Sales and Accelerate Pipeline
July 23, 2021
Anivive's GC376 Reduces COVID-19 Replication, Shows Potential as New Post-Infection Treatment
July 8, 2021
Anivive Awarded $500,000 Grant by the FDA for Canine Cancer Studies
July 7, 2021
Anivive Announces Publication Highlighting the First Successful Use of Artificial Intelligence in Diagnosing Valley Fever in Dogs
June 28, 2021
Anivive Expands Specialty Sales Team to Support Rapid National Distribution of LAVERDIA™-CA1 (verdinexor)
June 17, 2021
Anivive Announces Positive Study Results for Antifungal Vaccine to Prevent Canine Valley Fever
June 3, 2021
Anivive Highlighted in Scientific American Article on Breakthrough Fungal Vaccine
May 26, 2021
Anivive Announces Collaboration with MWI Animal Health to Provide Veterinarians with the Newest Lymphoma Treatment for Dogs
January 21, 2021
Anivive Announces FDA Conditional Approval of LAVERDIA™-CA1 (verdinexor) - the First and Only Oral Tablet to Treat Lymphoma in Dogs
View all press releases